Supporting Science in a world of COVID-19, 6th July 2020!

Whilst we are currently living in a world dominated by COVID-19, here at Baker, we feel it’s important to still continue to support scientific discoveries across the globe.

At Baker, nothing is more important to us than the trust you place in our solutions to help you achieve your goals. Whether you are involved in basic scientific research, drug discovery or patient care, we have proven that we have an uncompromising commitment to safety, testing, quality and craftsmanship.

1. Vaxart’s Oral Vaccine Candidate

The study of the vaccine candidate is designed to demonstrate the efficacy of Vaxart’s COVID-19 vaccine candidate, which is based on the company’s Vector-Adjuvant-Antigen Standardized Technology Platform.

On Friday, the vaccine developer stated that its room temperature stable tablet vaccine had been selected for a non-human primate (NHP) challenge study designed to provide up to 300 million vaccine doses by 2021.

Source

2. FDA Vaccine Expectations

The FDA has stated that it expects any COVID-19 vaccine that it licenses to be able to have the ability to either prevent or significantly decrease the severity of the disease.

The recommendation, which the FDA claims reflects the advice the agency has provided to developers throughout recent months was part of an overall document called “Development and Licensure of Vaccines to Prevent COVID-19”. The goal is for all vaccines to developed to be effective, but most importantly, safe.

Source

3. Parexel & TriNetX Partner to Advance Clinical Trials

Parexel and TriNetX will aim to work together to develop deeper and more usable insights into healthcare data, in order to accelerate the launch of clinical research studies, for example studies into COVID-19 .

According to the companies, the integrated offering will leverage Datavant’s privacy-protecting linking technology, therefore helping to enhance clinical trials and bring new therapies to the market faster.

Source

4. The World Organization Pitch for Budget of $31bn

The WHO and its allies have made a pitch for a budget, which aims to get COVID-19 vaccines and treatment tools to countries across the globe.

Ultimately, the WHO believe that the project will need more than $31bn through to the end of 2021. This investment and funding will provide vaccines, therapeutics and diagnostics to fight the disease.

Source

Stay Connected

Make sure you join us in #SupportingScience across all of our social media channels!

Sources

1. https://www.genengnews.com/news/vaxart-oral-covid-19-vaccine-joins-trumps-warp-speed-ramps-up-manufacturing-capacity/, 2. https://www.drugdiscoverytrends.com/covid-19-vaccines-need-to-work-at-least-half-of-the-time-fda-says/, 3. https://www.outsourcing-pharma.com/Article/2020/06/30/Parexel-TriNetX-partner-to-advance-RWD-in-clinical-trials, 4. https://covid19data.com/2020/06/27/the-big-budget-pandemic-to-provide-covid-19-treatment-vaccine-to-all-who-require-31-bn-by-2021-end/